<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03006055</url>
  </required_header>
  <id_info>
    <org_study_id>VIROAD01</org_study_id>
    <nct_id>NCT03006055</nct_id>
  </id_info>
  <brief_title>The Detection of Circulating Tumor Cells (CTCs) in Breast Cancer With a Novel in Vivo Device</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Viroad Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Viroad Biotechnology Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide which is CE
      approved. Application data of CellCollector in China is not available now. The purpose of
      this clinical trial is to confirm the validation and safety of CellCollector in Chinese
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Validation of CellCollector</measure>
    <time_frame>6 month</time_frame>
    <description>CTC enumeration and detection rate in Chinese patients with metastasis breast cancer will be analyzed by using CellCollector.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>6 month</time_frame>
    <description>Number of participants with treatment-related adverse events and blood IgE level will be analyzed after CellCollector application.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Circulating Tumor Cells.Breast</condition>
  <arm_group>
    <arm_group_label>MBC Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metastatic breast cancer Age：18-75 ECOG:0-2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>benign breast tumour Age：18-75 ECOG:0-2</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Circulating tumor cells</intervention_name>
    <arm_group_label>MBC Group</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastasis breast cancer confirmed with imaging examination

          -  Have agreed to undergo CTC analysis in vivo;

          -  ECOG：0-2

        Exclusion Criteria:

          -  Non-metastasis breast cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>YH Dong, MD</last_name>
    <phone>+86031189928691</phone>
    <email>dongyh_viroad@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The 307th Hospital of Chinese People's Liberation Army</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ZF Jiang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2016</study_first_submitted>
  <study_first_submitted_qc>December 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2016</study_first_posted>
  <last_update_submitted>December 29, 2016</last_update_submitted>
  <last_update_submitted_qc>December 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

